News-Medical.net The ATAC trial included nearly 10,000 women who were treated with surgery followed by five years of treatment with the drugs anastrozole , tamoxifen or...
The Information Daily "Cancer Research UK's crucial work in the laboratory is behind many important drugs, such as tamoxifen and herceptin, and our trials of drugs called aromatase inhibitors paved the way for the development of anastrozole – all of this is helping to give ...
General Surgery News The ATAC trial 10-year follow-up data demonstrated that late disease recurrence is a hallmark of estrogen receptor (ER)-positive breast cancer, with greater than 50% of recurrences occurring after five years of adjuvant tamoxifen or anastrozole therapy.
